(VIANEWS) – Shares of NeuroMetrix (NASDAQ: NURO) dropped by a staggering 16.39% in 5 sessions from $1.83 to $1.53 at 10:54 EST on Tuesday, after four sequential sessions in a row of losses. NASDAQ is jumping 1.98% to $11,410.76, following the last session’s upward trend.
NeuroMetrix’s last close was $1.49, 74.7% under its 52-week high of $5.89.
About NeuroMetrix
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.42.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.47%.
Yearly Top and Bottom Value
NeuroMetrix’s stock is valued at $1.53 at 10:54 EST, way below its 52-week high of $5.89 and way higher than its 52-week low of $1.33.
Volume
Today’s last reported volume for NeuroMetrix is 6153 which is 89.12% below its average volume of 56593.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NeuroMetrix’s stock is considered to be overbought (>=80).
More news about NeuroMetrix (NURO).
